- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04138173
Enhancing Physical Activity in Patients With Interstitial Lung Disease
Enhancing Physical Activity in Patients With Interstitial Lung Disease: an Exploratory Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The present study aims to
1) primary objective: To explore the magnitude of the effect of a semi-automated tele coaching intervention to enhance physical activity in patients with interstitial lung disease, as measured at 12 weeks, expressed as mean daily step count.
2) Secondary objectives:
- To test the magnitude of the effect of a 12 weeks coaching intervention on mean time in at least moderate intense activity, walking time, movement intensity, activity bout duration, exercise capacity, quadriceps force and health status.
- To investigate the patient's experience with this intervention
- To test the effect of a 12 weeks coaching intervention on the physical activity from a patient experience.
- To explore the relation between physical activity and vitamin D
Therefore, the study will include stable patients with interstitial lung disease who will be randomized into an intervention (semi-automated coaching intervention) and control (usual care) group. The study consists of a total of 3 visits.
- visit 1: Screening visit
- visit 2: Randomization visits, scheduled 1-2 weeks after visit 1
- visit 3: Follow-up visit, schedules 12 weeks after visit 2
Patients will be randomized into the intervention and control group. In both groups patients will receive information about the importance of being physically active and the physical activity recommendations provided by the world health organization. This information will be provided in a leaflet that will be discussed in an education session (one-to-one) of 10-15 minutes.
- The control group will receive usual care together with the educational information.
- Patients in the intervention group will receive a multicomponent tele coaching intervention that consists of 1) education about the importance of physical activity and a one-to-one interview with the coach discussing motivation and barriers to be active, 2) a step counter providing direct feedback, 3) application installed on a smartphone providing an adaptive goal and daily and weekly feedback and 4) contact with the coach if the patient is not compliant with the intervention or not increasing physical activity. The patient is asked to have a daily interaction with the smartphone application.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- KULeuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stable patients, older than 18 year, with a diagnosis of interstitial lung disease
- Understand and able to work with a smartphone application, as judged by the investigator
- On stable pharmacotherapy
- DLCO ≥30%predicted
Exclusion Criteria:
- On the waiting list for a lung transplantation
- Life expectancy below 3 months
- Respiratory tract infection or an exacerbation or change in maintenance medication within 4 weeks before study enrolment
- Extra pulmonary impairments, unrelated to the underlying lung disease, interfering with physical activity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Tele coaching group
Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
|
A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B. Step counter providing direct feedback. C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed. |
NO_INTERVENTION: Usual care group
Usual care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily number of steps at 12 weeks
Time Frame: 12 weeks
|
Change in weekly mean step count 12 weeks post randomization in the intervention group as compared to the control group.
Physical activity will be objectively measured for 1 week using a tri-axial accelerometer (Dynaport Movemonitor) validated for use in in chronic respiratory disease.
Data obtained on days with more than 8 hours of wearing time will be used for further analysis.
A measurement will be considered valid when having more than four valid days.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time spent in at least moderate intense activity
Time Frame: 12 weeks
|
Change in daily time spent in at least moderate intense activity 12 weeks post randomization in the intervention group as compared to the control group.
Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease.
Data obtained on days with more than 8 hours of wearing time will be used for further analysis.
|
12 weeks
|
Mean walking time per day
Time Frame: 12 weeks
|
Change in mean daily walking time 12 weeks post randomization in the intervention group as compared to the control group.
Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease.
Data obtained on days with more than 8 hours of wearing time will be used for further analysis.
|
12 weeks
|
Movement intensity
Time Frame: 12 weeks
|
Change in mean movement intensity 12 weeks post randomization in the intervention group as compared to the control group.
Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease.
Data obtained on days with more than 8 hours of wearing time will be used for further analysis.
|
12 weeks
|
Activity bout duration
Time Frame: 12 weeks
|
Change in mean duration of an activity bout 12 weeks post randomization in the intervention group as compared to the control group.
Physical activity will be objectively measured for 1 week using a tri-axial accelerometer validated for use in in chronic respiratory disease.
Data obtained on days with more than 8 hours of wearing time will be used for further analysis.
|
12 weeks
|
Exercise capacity
Time Frame: 12 weeks
|
Change in six-minutes walk distance 12 weeks post randomization in the intervention group as compared to the control group.
The six-minute walking test will be performed with standardized encouragement to assess patients' functional exercise capacity.
The best of two measurements will be used.
|
12 weeks
|
Maximal voluntary isometric quadriceps force
Time Frame: 12 weeks
|
Change in isometric quadriceps force 12 weeks post randomization in the intervention group as compared to the control group.
The quadriceps isometric strength will be evaluated by a maximal voluntary contraction using the Biodex, a computerized dynamometer.
Patients will be seated with a 90° hip and 60° knee flexion.
The best of 3 measurements will be taken into analysis as the maximal force capacity of the lower limb.
|
12 weeks
|
Health status
Time Frame: 12 weeks
|
Health status will be measured by the The King's Brief Interstitial Lung disease (K-BILD) questionnaire.
The K-BILD questionnaire is a valid self-completed health status measure for patients with interstitial lung disease consisting of 15 items that measures health status in 3 domains (Psychological, Breathlessness and activity and chest symptoms) and a total score.
|
12 weeks
|
Symptoms of anxiety and depression
Time Frame: 12 weeks
|
Symptoms of anxiety and depression will be measured by the Hospital Anxiety and Depression Scale (HADs).
The HADs is a generic screening measure of symptoms of anxiety and depression.
The HADS is a 14 item measure comprising 7 anxiety items and 7 depression items from which separate anxiety and depression sub-scale scores are calculated.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity from a patient's perspective (Exploratory endpoint)
Time Frame: 12 weeks
|
The c-PPAC, a 12-item questionnaire assessing physical activity from a patient's perspective reflecting the past 7 days will be collected.
The questionnaire investigates the amount of and difficulty with physical activity as perceived by the patient.
The 2 domain scores (i.e.
amount and difficult) as well as the total score will be retrieved as outcomes.
|
12 weeks
|
Time to first hospital admission
Time Frame: 2 year
|
For explanatory purposes, time to first hospital admissions will be collected in these patients in the 2 years following on the present study.
|
2 year
|
Transplantation free survival
Time Frame: 2 year
|
For explanatory purposes, transplantation free survival status will be collected in these patients in the 2 years following on the present study.
|
2 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thierry Trooosters, Prof, KU Leuven
- Principal Investigator: Heleen Demeyer, Prof, KU Leuven
- Principal Investigator: Wim Wuyts, Prof, KU Leuven
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S62505
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Lung Disease
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Matthias GrieseSuspendedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationNot yet recruitingFibrotic Interstitial Lung Disease
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Heidelberg UniversityHelmholtz Zentrum München; University of Giessen; Lungenfibrose e.V.; German Center... and other collaboratorsCompletedInterstitial Lung Disease (ILD)Germany
-
University of California, San FranciscoTerminatedFibrotic Interstitial Lung DiseaseUnited States
-
Saglik Bilimleri UniversitesiRecruitingTelerehabilitation | Fibrosing Interstitial Lung DiseaseTurkey
-
University of AarhusAarhus University HospitalNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseDenmark
-
West Virginia UniversityNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseUnited States
Clinical Trials on Tele coaching intervention
-
Palacky UniversityKU LeuvenRecruiting
-
Boston Children's HospitalJohns Hopkins University; University of Kansas Medical Center; Cystic Fibrosis... and other collaboratorsCompletedCystic FibrosisUnited States
-
Case Western Reserve UniversityCompletedMultiple Sclerosis | CaregiversUnited States
-
Northumbria UniversityNewcastle-upon-Tyne Hospitals NHS TrustUnknownLung Transplant RecipientsUnited Kingdom
-
Pennington Biomedical Research CenterLouisiana State University Health Care Services DivisionCompletedHypertension | Obesity | Diabetes | OverweightUnited States
-
Mayo ClinicPreventiceCompleted
-
University Hospital, GhentHasselt University; Jessa Hospital; AZ Sint-Jan AV; AZ Delta; Ziekenhuis Oost-LimburgRecruitingNon Small Cell Lung Cancer | Non-small Cell CarcinomaBelgium
-
University of TorontoYMCA; Ontario HIV Treatment NetworkCompleted
-
KU LeuvenCompleted